Top Markets
#1 Verus Coin Verus Coin +22.44%
#2 Ontology Gas Ontology Gas +19.53%
#3 Status Status +17.90%
#4 ETHGas ETHGas +15.70%
#5 Geodnet Geodnet +13.21%
#6 Derive Derive +12.82%
#7 Curve DAO Curve DAO +11.62%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +9.94%
#9 Anvil Anvil +9.76%
#10 The Black Bull The Black Bull +9.10%
Coin of the day
Verus Coin Verus Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Carna Biosciences, Inc. Carna Biosciences, Inc.

Carna Biosciences, Inc.

4572
Rank in Stocks #25406
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a... Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Share Price
$2.62
Market Cap
$50.19M
Change (1 day)
-1.47%
Change (1 year)
77.21%
Country
JP
Trade Carna Biosciences, Inc. (4572)

Category

Healthcare
Operating Margin for Carna Biosciences, Inc. (4572)
Operating Margin as of 2026 TTM: 0.00%
According to Carna Biosciences, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Carna Biosciences, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.